This leads to phosphorylation and proteasomal degradation of IκBα followed by nuclear translocation of NF-κB subunits to activate transcription of NF-κB target genes. NF-κB-responsive genes comprise pro-inflammatory genes, for example TNFα and interleukin-8, antiapoptotic genes such as XIAP, Bcl-2 or Bcl-X L , as well as proapoptotic genes such CD95 and TRAIL receptors (5) . cIAP proteins promote canonical NF-κB activation by ubiquitinating RIP1 (3).
Within the non-canonical NF-κB pathway, cIAP proteins mediate under resting conditions the constitutive ubiquitination and proteasomal degradation of NF-κB-Inducing Kinase (NIK) together with TRAF2 and TRAF3, thereby negatively regulating non-canonical NF-κB signaling (7, 8) . Activation of non-canonical NF-κB signaling, e.g. in response to CD40 stimulation, terminates this cIAPdependent NIK degradation and allows activation of IKKα via NIK, followed by processing of p100 to p52 and translocation of p52 to the nucleus to activate NF-κB target genes (9) .
Research. (13, 14) . cIAP proteins have been shown to be required for activation of MAPK signaling by members of the TNFR superfamily (10). XIAP has been described to function as a cofactor in TGFβ signaling (11) . The immunomodulatory functions of IAP proteins are mediated via their regulation of NF-κB and MAPK signaling pathways or via the control of the activity of the inflammasome, a multiprotein complex that regulates an immune response to microbial triggers (13) . Evaluation of IAP antagonists as single agents revealed that they effectively trigger cell death in a small subset of human malignancies (19) , indicating that In addition to enhancing the antitumor activity of DNA-damaging drugs, IAP antagonists have been reported to increase radiosensitivity in various cancers (27, (33) (34) (35) (36) . Interestingly, radiosensitization by IAP antagonists was not restricted to the bulk population of the tumor, but was also found in tumor-initiating cancer stem cells that have been described to be particularly radioresistant (27) .
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